- Translational Research in Diabetes and Obesity: Exciting Collaborations at NYULMC
- Carmen Hurtado del Pozo, PhD, received the Mentor-Based Postdoctoral Minority Fellowship Award from the American Diabetes Association.
- Ann Marie Schmidt MD and Ravi Ramasamy, PhD were awarded a Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24) grant from the NIH/NIDDK. <<more>>
Dr. Ramasamy has been granted tenure by the University. Effective July 1, 2014.
- Karen O'Shea, PhD, is the Diabetes Research Program Researcher of the Month
- On May 14, 2014, the Department of Medicine held its 13th Annual Research Day. Among the participants were several members of the Diabetes Research Program. <<more>>
- The Diabetes Research Program and NYU's Initiative in Data Science and Statistics were awarded a research grant from Independence Blue Cross. The goal of this collaboration is twofold; detect undiagnosed diabetes cases and predict potential cases of the disease. <<more>>
- Ann Marie Schmidt, MD and Ravi Ramasamy, PhD were awarded a grant from the NYU Abu Dhabi Institute. In collaboration with the NYU Abu Dhabi Public Health Research Institute, the project will examine the growing obesity and diabetes epidemic in Abu Dhabi.
- More News & Highlights
Diabetes Research Program
As the incidence of both types 1 and 2 diabetes rises in the United States and throughout the world, the risk of the devastating complications soars as well. Diabetes is a leading cause of heart attacks, strokes, blindness, kidney failure and amputations. The vast morbidity and mortality exacted by the disease cause considerable loss of quality of life and are a major burden to the health care system. Our laboratory group is focused on the study of the biochemical and molecular mechanisms that underlie the complications of diabetes, particularly the links between hyperglycemia, inflammation and diabetic tissue damage. We focus on key molecules linked to diabetes, such as aldose reductase, Protein Kinase C-β, receptor for AGE (RAGE) and its cytoplasmic domain binding partner, diaphanous 1 or mDia1. Our research team uses a variety of techniques to address these concepts experimentally, from animal models of diabetes to gene regulation studies in cultured cells. Our goal is to transform basic science discoveries into validated targets for therapeutic intervention in diabetes and its complications.